{"slideshow_credits": null, "snippet": "Development of the drug, aleglitazar, was discontinued after Roche cited concerns about safety and effectiveness.", "abstract": "Roche discontinues development of potentially important diabetes drug aleglitazar, move that could raise safety questions about entire category of drugs, which includes controversial medicine Avandia.", "section_name": "Business Day", "print_page": "3", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/07/11/business/roche-abandons-new-diabetes-drug.html", "lead_paragraph": "Development of the drug, aleglitazar, was discontinued after Roche cited concerns about safety and effectiveness.", "headline": {"main": "Roche Stops Developing a New Drug for Diabetes", "print_headline": "Roche Stops Developing A New Drug For Diabetes"}, "_id": "51dd0b8f7e0d9c0839d2eeef", "word_count": "689", "multimedia": [], "pub_date": "2013-07-11T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Diabetes", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Roche Holding AG", "name": "organizations", "is_major": "Y", "rank": "3"}], "blog": [], "subsection_name": null, "type_of_material": "News"}